000120082 001__ 120082
000120082 005__ 20240228135011.0
000120082 0247_ $$2doi$$a10.1016/j.ijrobp.2013.12.039
000120082 0247_ $$2pmid$$apmid:24661667
000120082 0247_ $$2ISSN$$a0360-3016
000120082 0247_ $$2ISSN$$a1879-355X
000120082 037__ $$aDKFZ-2017-00669
000120082 041__ $$aeng
000120082 082__ $$a610
000120082 1001_ $$aGillmann, Clarissa$$b0
000120082 245__ $$aTemporal lobe reactions after carbon ion radiation therapy: comparison of relative biological effectiveness-weighted tolerance doses predicted by local effect models I and IV.15
000120082 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2014
000120082 3367_ $$2DRIVER$$aarticle
000120082 3367_ $$2DataCite$$aOutput Types/Journal article
000120082 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1490789204_9393
000120082 3367_ $$2BibTeX$$aARTICLE
000120082 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120082 3367_ $$00$$2EndNote$$aJournal Article
000120082 520__ $$aTo compare the relative biological effectiveness (RBE)-weighted tolerance doses for temporal lobe reactions after carbon ion radiation therapy using 2 different versions of the local effect model (LEM I vs LEM IV) for the same patient collective under identical conditions.In a previous study, 59 patients were investigated, of whom 10 experienced temporal lobe reactions (TLR) after carbon ion radiation therapy for low-grade skull-base chordoma and chondrosarcoma at Helmholtzzentrum für Schwerionenforschung (GSI) in Darmstadt, Germany in 2002 and 2003. TLR were detected as visible contrast enhancements on T1-weighted MRI images within a median follow-up time of 2.5 years. Although the derived RBE-weighted temporal lobe doses were based on the clinically applied LEM I, we have now recalculated the RBE-weighted dose distributions using LEM IV and derived dose-response curves with Dmax,V-1 cm³ (the RBE-weighted maximum dose in the remaining temporal lobe volume, excluding the volume of 1 cm³ with the highest dose) as an independent dosimetric variable. The resulting RBE-weighted tolerance doses were compared with those of the previous study to assess the clinical impact of LEM IV relative to LEM I.The dose-response curve of LEM IV is shifted toward higher values compared to that of LEM I. The RBE-weighted tolerance dose for a 5% complication probability (TD5) increases from 68.8 ± 3.3 to 78.3 ± 4.3 Gy (RBE) for LEM IV as compared to LEM I.LEM IV predicts a clinically significant increase of the RBE-weighted tolerance doses for the temporal lobe as compared to the currently applied LEM I. The limited available photon data do not allow a final conclusion as to whether RBE predictions of LEM I or LEM IV better fit better clinical experience in photon therapy. The decision about a future clinical application of LEM IV therefore requires additional analysis of temporal lobe reactions in a comparable photon-treated collective using the same dosimetric variable as in the present study.
000120082 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120082 588__ $$aDataset connected to CrossRef, PubMed,
000120082 650_7 $$2NLM Chemicals$$aIons
000120082 650_7 $$07440-44-0$$2NLM Chemicals$$aCarbon
000120082 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b1$$udkfz
000120082 7001_ $$aSchlampp, Ingmar$$b2
000120082 7001_ $$0P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aKarger, Christian$$b3$$eLast author$$udkfz
000120082 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2013.12.039$$gVol. 88, no. 5, p. 1136 - 1141$$n5$$p1136 - 1141$$tInternational journal of radiation oncology, biology, physics$$v88$$x0360-3016$$y2014
000120082 909CO $$ooai:inrepo02.dkfz.de:120082$$pVDB
000120082 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000120082 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000120082 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120082 9141_ $$y2014
000120082 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120082 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2015
000120082 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120082 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120082 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120082 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120082 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120082 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120082 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120082 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120082 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120082 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120082 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120082 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120082 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x0
000120082 980__ $$ajournal
000120082 980__ $$aVDB
000120082 980__ $$aI:(DE-He78)E040-20160331
000120082 980__ $$aUNRESTRICTED